Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for AbbVie Inc. (ABBV : NYSE)
 
 • Company Description   
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.

Number of Employees: 50,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $151.01 Daily Weekly Monthly
20 Day Moving Average: 7,565,887 shares
Shares Outstanding: 1,767.11 (millions)
Market Capitalization: $266,851.28 (millions)
Beta: 0.83
52 Week High: $175.91
52 Week Low: $105.56
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -2.57% 6.68%
12 Week 0.98% 13.49%
Year To Date 11.53% 36.25%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1 NORTH WAUKEGAN ROAD
-
NORTH CHICAGO,IL 60064
USA
ph: 847-932-7900
fax: 302-655-5049
None http://www.abbvie.com
 
 • General Corporate Information   
Officers
Richard A. Gonzalez - Chairman of the Board and Chief Executive Officer
Robert A. Michael - Vice Chairman; Finance and Commercial Operations a
Brian L. Durkin - Vice President; Controller
Roxanne S. Austin - Director
Thomas C. Freyman - Director

Peer Information
AbbVie Inc. (AGN.)
AbbVie Inc. (ABBV)
AbbVie Inc. (NVO)
AbbVie Inc. (LLY)
AbbVie Inc. (RHHBY)
AbbVie Inc. (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 00287Y109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 07/29/22
Share - Related Items
Shares Outstanding: 1,767.11
Most Recent Split Date: (:1)
Beta: 0.83
Market Capitalization: $266,851.28 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 3.73%
Current Fiscal Quarter EPS Consensus Estimate: $3.43 Indicated Annual Dividend: $5.64
Current Fiscal Year EPS Consensus Estimate: $14.06 Payout Ratio: 0.44
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: -0.04
Estmated Long-Term EPS Growth Rate: 2.54% Last Dividend Paid: 04/13/2022 - $1.41
Next EPS Report Date: 07/29/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 10.74
Trailing 12 Months: 11.70
PEG Ratio: 4.24
Price Ratios
Price/Book: 16.36
Price/Cash Flow: 8.55
Price / Sales: 4.70
EPS Growth
vs. Year Ago Period: 7.12%
vs. Previous Quarter: -4.53%
Sales Growth
vs. Year Ago Period: 4.06%
vs. Previous Quarter: -9.06%
ROE
03/31/22 - 159.31
12/31/21 - 164.05
09/30/21 - 166.05
ROA
03/31/22 - 15.73
12/31/21 - 15.29
09/30/21 - 14.72
Current Ratio
03/31/22 - 0.82
12/31/21 - 0.79
09/30/21 - 1.01
Quick Ratio
03/31/22 - 0.71
12/31/21 - 0.70
09/30/21 - 0.91
Operating Margin
03/31/22 - 40.67
12/31/21 - 40.39
09/30/21 - 39.88
Net Margin
03/31/22 - 22.00
12/31/21 - 20.54
09/30/21 - 13.66
Pre-Tax Margin
03/31/22 - 24.77
12/31/21 - 23.11
09/30/21 - 13.07
Book Value
03/31/22 - 9.23
12/31/21 - 8.73
09/30/21 - 7.68
Inventory Turnover
03/31/22 - 5.28
12/31/21 - 5.42
09/30/21 - 5.45
Debt-to-Equity
03/31/22 - 3.89
12/31/21 - 4.16
09/30/21 - 5.45
Debt-to-Capital
03/31/22 - 79.57
12/31/21 - 80.61
09/30/21 - 84.51
 

Powered by Zacks Investment Research ©